Wegovy Oral Pill Surges as Novo Nordisk Tests Lower Doses, Prices Drop and Generics Emerge

# Wegovy in 2025: The Real-Time Story of Medicine, Money, and Policy Colliding **Podcast Episode Description:** Wegovy is no longer just a weight-loss drug — it's become a global case study in how modern medicine intersects with pharmaceutical economics, healthcare policy, and everyday life. In this episode, we unpack the latest developments reshaping the Wegovy story, drawing on reporting from Reuters, Bloomberg, Politico, USA Today, and more. We break down Novo Nordisk's newly launched OASIS 5 trial, a late-stage study testing lower maintenance doses of oral Wegovy in hopes of maintaining efficacy while reducing side effects and cost. We explore how oral Wegovy prescriptions have surged to record highs in the U.S., now representing over a third of all Wegovy scripts — and how Eli Lilly's competing pill, Foundayo, is entering the UK market, intensifying the race for GLP-1 dominance. The episode also digs into the economics behind the headlines: transatlantic pricing differences, Novo's planned 2027 price cut, the Trump administration's Medicaid pricing deal (and why most states are rejecting it), and the emergence of potential generic competitors like Celon Pharma's Reduzek. Beyond weight loss, we examine Wegovy's expanding medical footprint — from cardiovascular risk reduction to an FDA submission targeting MASH (liver disease) — and highlight new safety data across diverse patient populations. We even cover the surprisingly strict daily ritual patients must follow, including why your morning coffee could interfere with the drug's effectiveness. This episode connects the clinical, financial, and personal dimensions of the Wegovy phenomenon — showing how a single medication has become a lens for understanding modern healthcare's biggest questions: Who gets access? Who pays? And how do global markets respond when science, business, and human need collide? **Topics covered:** Wegovy oral pill, semaglutide, Novo Nordisk, Eli Lilly Foundayo, GLP-1 drugs, obesity treatment, Medicaid drug pricing, MASH liver disease, weight loss drug economics, pharmaceutical policy, OASIS 5 trial, generic semaglutide, healthcare affordability **Perfect for:** Listeners interested in healthcare policy Some great Deals https://amzn.to/49SJ3Qs For more check out http://www.quietplease.ai